TNBC, which lacks the expressions of ER, PR and HER-2/neu and accounts for 15%–20% of breast cancer cases, is considered the most severe and difficult-to-treat disease as it is unresponsive to many hormone-based therapies because of their lack of receptors. This evidence concerns the gene ERBB2 and breast carcinoma.